Medicare Part D Coverage and Costs for Glucagon-Like Peptide-1 Receptor Agonists
JAMA · 25.11.2025 · 334 (20) · 1848
DOI: 10.1001/jama.2025.15841 ↗Kurz gefasst
Fachartikel in der Zeitschrift JAMA, erschienen am 25.11.2025. Verfasst von Matthew J Klebanoff und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of General Internal Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 6 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
This cross-sectional study examines Medicare Part D coverage and out-of-pocket costs for glucagon-like peptide-1 receptor agonists following implementation of the Inflation Reduction Act.
Autor:innen und Institutionen
- Division of General Internal Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia.
- Leonard Davis Institute of Health Economics, Philadelphia, Pennsylvania.
- Philadelphia VA Center for Healthcare Evaluation, Research, and Promotion, Philadelphia, Pennsylvania.
Zitieren
APA
Klebanoff, M. J., Li, P., Long, J. A., & Doshi, J. A. (2025). Medicare Part D Coverage and Costs for Glucagon-Like Peptide-1 Receptor Agonists. JAMA, 334(20), 1848. https://doi.org/10.1001/jama.2025.15841
Vancouver
Klebanoff MJ, Li P, Long JA, Doshi JA. Medicare Part D Coverage and Costs for Glucagon-Like Peptide-1 Receptor Agonists. JAMA. 2025;334(20):1848. doi:10.1001/jama.2025.15841
BibTeX
@article{Klebanoff2025,
author = {Klebanoff, Matthew J and Li, Pengxiang and Long, Judith A and Doshi, Jalpa A},
title = {Medicare Part D Coverage and Costs for Glucagon-Like Peptide-1 Receptor Agonists},
journal = {JAMA},
year = {2025},
volume = {334},
number = {20},
pages = {1848},
doi = {10.1001/jama.2025.15841}
}
EUVIMED